High Risk Neuroblastoma Clinical Trials

13 recruitingLast updated: June 18, 2026

There are 13 actively recruiting high risk neuroblastoma clinical trials across 23 countries. Studies span Phase 1, Phase 2, Phase 3, Not Applicable. Top locations include Philadelphia, Pennsylvania, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


High Risk Neuroblastoma Trials at a Glance

13 actively recruiting trials for high risk neuroblastoma are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Philadelphia, New York, and Boston. Lead sponsors running high risk neuroblastoma studies include Memorial Sloan Kettering Cancer Center, Stephan Grupp MD PhD, and Fundación de investigación HM.

Browse high risk neuroblastoma trials by phase

Treatments under study

About High Risk Neuroblastoma Clinical Trials

Looking for clinical trials for High Risk Neuroblastoma? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new High Risk Neuroblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about High Risk Neuroblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NeuroblastomaHigh Risk NeuroblastomaMetastatic Neuroblastoma
Memorial Sloan Kettering Cancer Center94 enrolled7 locationsNCT06057948
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 2Phase 3

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

High Risk Neuroblastoma
Renaissance Pharma Ltd.144 enrolled2 locationsNCT07549321
Recruiting

Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors

High Risk Neuroblastoma
St. Jude Children's Research Hospital45 enrolled1 locationNCT06480526
Recruiting
Phase 1Phase 2

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Beijing Biotech36 enrolled1 locationNCT07502287
Recruiting
Phase 2

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

NeuroblastomaHigh Risk NeuroblastomaChildhood Neuroblastoma
Memorial Sloan Kettering Cancer Center45 enrolled1 locationNCT06528496
Recruiting
Not Applicable

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

NeuroblastomaHigh Risk Neuroblastoma
Dana-Farber Cancer Institute84 enrolled6 locationsNCT06831552
Recruiting
Phase 1Phase 2

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma
Roberto Chiarle42 enrolled2 locationsNCT06803875
Recruiting
Phase 1

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

High Risk NeuroblastomaRetinoblastomaRefractory Neuroblastoma+2 more
Stephan Grupp MD PhD45 enrolled1 locationNCT05650749
Recruiting
Phase 1

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma
Stephan Grupp MD PhD38 enrolled1 locationNCT07007117
Recruiting
Phase 3

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

High Risk NeuroblastomaPatient With Insufficient Response Chemoimmunotherapy
Gustave Roussy, Cancer Campus, Grand Paris800 enrolled142 locationsNCT04221035
Recruiting
Phase 1

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

SarcomaSCLCMalignant Melanoma+1 more
Y-mAbs Therapeutics60 enrolled8 locationsNCT05130255
Recruiting
Phase 1

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

High Risk Neuroblastoma
Jagiellonian University20 enrolled1 locationNCT05272371